Help us revolutionize the way drugs are discovered & developed!
Currently, it takes on average 12 years and $2.6 billion to get a single drug to market, with the drug discovery and development process costing $1.4 billion. Last year, Verge Genomics raised $32 million in Series A financing to change this broken model by fueling the drug discovery pipeline with machine learning.
Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development.
We are looking for extraordinary individuals to join our motivated team in taking on our generation’s biggest healthcare challenges: ALS, Parkinson’s Disease, and Alzheimer's Disease. Our employees are our most important asset; we are a team of founders, excited to learn, roll up our sleeves, and make a real impact.
The startup nature of Verge Genomics provides multiple growth opportunities into other areas of the company. As one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, on-site gym access, and free lunch.
Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Currently, it takes on average 12 years and $2.6 billion to get a single drug to market, with the drug discovery and development process costing $1.4 billion. Last year, Verge Genomics raised $32 million in Series A financing to change this broken model by fueling the drug discovery pipeline with machine learning.
Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development.
We are looking for extraordinary individuals to join our motivated team in taking on our generation’s biggest healthcare challenges: ALS, Parkinson’s Disease, and Alzheimer's Disease. Our employees are our most important asset; we are a team of founders, excited to learn, roll up our sleeves, and make a real impact.
The startup nature of Verge Genomics provides multiple growth opportunities into other areas of the company. As one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, on-site gym access, and free lunch.
Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $68M
Founded date: 2015
Investors 14
Show more
Funding Rounds 3
Date | Series | Amount | Investors |
17.07.2018 | Series A | $32M | - |
16.07.2018 | Series B | $32M | - |
03.11.2015 | Seed | $4M | - |
Persons 1
Date | First Name | Last Name | Title | |||
- | Naveen | Jain | Investor | linkedin.c... | - | - |
Mentions in press and media 32
Date | Title | Description |
17.08.2023 | The CEO of Verge Genomics shares how she's overcome gender and age biases in biotech by showing people 'there can be a new way of doing things' | Alice Zhang is CEO and cofounder of Verge Genomics Verge Genomics Redeem now Alice Zhang started Verge Genomics in 2015 to rethink the drug discovery process. In the latest Equity Talk, she shares how she's overcoming biases in the VC and b... |
24.05.2023 | Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical Trial | Emerald AI platform and “invisible” sensors to capture critical patient data and measure changes in clinical function in patients treated with VRG50635 Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use ... |
13.02.2023 | The 8 leading biotechs using AI to upend how drugs are discovered | Recursion Pharmaceuticals' laboratory in Salt Lake City. Recursion Pharmaceuticals This story is available exclusively to Insider subscribers. Become an Insider and start reading now. A few biotech companies have used AI to develop drugs th... |
15.11.2022 | Alice Zhang, CEO & Co-founder of Verge Genomics, Recognized by Both Fortune and Fierce Biotech as Pioneer in AI-Driven Drug Discovery | Verge Genomics, a clinical-stage, tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs for complex diseases, announced that Alice Zhang, CEO and co-founder of Verge Genom... |
16.12.2021 | Verge Genomics Announces $98M Series B | SAN FRANCISCO, CA, Verge Genomics announced today it has closed an oversubscribed $98 million equity financing. >> Click here for more funding data on Verge Genomics >> To export Verge Genomics funding data to PDF and Excel,... |
16.12.2021 | Verge Genomics Secures $98 Million in New Financing | Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing. The Series B financi... |
08.07.2021 | Eli Lilly looks to startup Verge Genomics to turn AI analysis into new ALS drugs | Amyotrophic lateral sclerosis (ALS) research has revealed genetic mutations linked to the motor neuron death characteristic of the disease. While such research is generating drug candidates, their reach will be limited, according to Verge G... |
02.02.2021 | Verge Genomics Announces Research Collaboration with the Sheffield Institute for Translational Neuroscience | "This collaboration strengthens our mission to find treatments for patients with neurodegenerative diseases," said Jane Rhodes, PhD, CBO SAN FRANCISCO (PRWEB) February 02, 2021 Verge Genomics, a drug discovery company developing t... |
31.01.2021 | Top 10 Female-founded Startups Revolutionizing The Tech Industry | One of the biggest issues facing the startup ecosystem of the world today is the gender bias experienced by females in business. This particular problem has reflected in several areas and especially in the fund procurement process of female... |
16.06.2020 | World Economic Forum’s 2020 Technology Pioneers highlight AI’s reach | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! The World Economic Forum (WEF) today announced th... |
Show more